trending Market Intelligence /marketintelligence/en/news-insights/trending/8RWOzodonHyJKeLifPve2A2 content esgSubNav
In This List

Sevion Therapeutics plans 1-for-20 reverse stock split

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Sevion Therapeutics plans 1-for-20 reverse stock split

Sevion Therapeutics, Inc.'s board approved a 1-for-20 reverse stock split, effective 4 p.m. on Dec. 19.

The company's stockholders approved the reverse stock split on Dec. 7, which will help Sevion satisfy the minimum bid price requirement for initial listing on the Nasdaq Capital Market.

The reverse split will reduce the number of outstanding common shares to about 2.6 million shares from about 51.4 million shares.

American Stock Transfer & Trust Co. will act as the exchange agent for the reverse stock split.